here we describe the second reported case of cannabinoid hyperemesis in uk. a 42 years old patient presented on more than one occasion with vomiting, abdominal pain, fever and dehydration and treated as sepsis with antibiotics. extensive investigations including upper gi endoscopy, colonoscopy, chest x-ray, abdominal ultrasound, abdominal ct scan, barium swallow and echocardiogram; all reported...

conclusions the important role played by endocannabinoid system promises interesting developments, in particular to evaluate the effectiveness of new drugs in both psychiatry and neurology. materials and methods the article is a critical analysis of the most recent data currently present in scientific literature on the subject; a qualitative synthesis of only the most significant articles has b...

Introduction: Nucleus cuneiformis (NCF), as part of descending pain inhibitory system, cooperates with periaqueductal gray (PAG) and rostral ventromedial medulla (RVM) in supraspinal modulation of pain. Cannabinoids have analgesic effects in the PAG, RVM and NCF. The transient receptor potential vanilloid type 1(TRPV1) can be activated by anandamide and WIN55,212-2 as a cannabinoid receptor ago...

The cannabinoid receptor 1 (CB(1)) and CB(2) cannabinoid receptors, associated with drugs of abuse, may provide a means to treat pain, mood, and addiction disorders affecting widespread segments of society. Whether the orphan G-protein coupled receptor GPR55 is also a cannabinoid receptor remains unclear as a result of conflicting pharmacological studies. GPR55 has been reported to be activated...

(?)-Cannabidiol (CBD) is a non-psychoactive compound that has already found many medical applications, from the treatment of epilepsy to other neurological disorders. (?)-CBD usually extracted Cannabis Sativa, but unfortunately, its isolation among structurally related cannabinoids can be challenging. This, along with increased demand for (?)-CBD, prompted chemists come up synthetic strategies ...

AM 251 ALX-270-239-M001 1 mg ALX-270-239-M005 5 mg Structurally related to the cannabinoid receptor (CB) antagonist SR 141716A. Binds with high affinity to cannabinoid receptor CB1 (Ki=7.49nM; 306-fold selective over CB2 receptors). LIT: Binding of the non-classical cannabinoid CP 55, 940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors: S.J. Gatley, et al.; Life Sci. 61, PL ...

Marijuana is the most commonly abused drug in the United States.1 It mainly acts on cannabinoid receptors. There are two types of cannabinoid receptors in humans: cannabinoid receptor type 1 (CB1) and cannabinoid receptor type 2 (CB2). CB1 receptor activation is pro-atherogenic, and CB2 receptor activation is largely anti-atherogenic. Marijuana use is also implicated as a trigger for myocardial...

This chapter will review the basic pharmacology of endocannabinoid receptors. As the best-described cannabinoid receptors are G-protein-coupled receptors (GPCRs), those will be the focus of this chapter. We will start with a basic review of GPCR signaling, as these concepts are critical to understanding the function of cannabinoid receptors. Next, several features of cannabinoid receptor signal...

Understanding cannabis and synthetic cannabinoid intake history is vital for treating drug dependence, investigating cannabinoid effects, and providing information to healthcare personnel, medical examiners, and public health officials; this is particularly relevant today with cannabis medicalization and legalization. Required information includes identifying exposure, time of use, frequency of...

Ten years elapsed since the discovery by Sanofi of SR141716A the first selective CB(1) cannabinoid receptor antagonist. Shortly after, Sanofi also reported the synthesis of the first selective CB(2) cannabinoid receptor antagonist, SR144528. Since these two milestones in the cannabinoid field, many other compounds, more or less related to the Sanofi compounds, or based on a completely different...